Sanofi Halts Phase 3 MOBILIZE Study on Riliprubart Following Unfavorable Interim Analysis
Sanofi announced on Wednesday the discontinuation of its Phase 3 MOBILIZE study on riliprubart, a drug candidate for patients with refractory chronic inflammatory demyelinating polyneuropathy (CIDP). This decision was made following an interim analysis by an independent data monitoring committee, which concluded that the study was unlikely to demonstrate sufficient efficacy.
The interim analysis of the MOBILIZE study (clinical identifier NCT06290128) determined that riliprubart would not produce the expected efficacy results in its target population. However, the independent data monitoring committee identified no safety signals related to riliprubart during this analysis.
Further Trials with Riliprubart to be Evaluated
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Sanofi indicated that the continuation of other ongoing studies with riliprubart, including the Phase 3 VITALIZE trial (clinical identifier NCT06290141) conducted among CIDP patients treated with intravenous immunoglobulins (IVIg), will be evaluated accordingly. The company is committed to closely supporting investigators and site teams to ensure an orderly conclusion of MOBILIZE, with proper follow-up for all included patients.
No Major Financial Impact
The discontinuation of the MOBILIZE trial will not result in significant financial costs for Sanofi. The company confirmed that there are no changes to its financial guidance for 2026.
SectorPharmacie et biotechnologies›Vaccins et laboratoires de recherche
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 22 106 millions d'euros
Quarterly revenue: 22 106 millions d'euros
Revenue growth: 11,1 %
Net income: 1 957 millions d'euros
Free cash flow: 3 724 millions d'euros
15 513 millions d'euros
Outlook / guidance
Expected revenue: 47 989 millions d'euros
Management commentary: Sanofi anticipe un taux de croissance autour de 10% à TCC, et prévoit pour le BNPA des activités à TCC une croissance légèrement supérieure à celle des ventes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
